Adjuvant therapy for renal cell carcinoma, finally a new standard?

Alex Renner, Carlos Rojas, Annerleim Walton-Diaz, Mauricio Burotto*

*Autor correspondiente de este trabajo

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

1 Cita (Scopus)


Localized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts have been made to identify effective strategies, with mostly negative results. However, recent results with immune checkpoint inhibitors may change the current standard, and several ongoing trials are exploring new alternatives. In this perspective, we aim to provide an overview of previous adjuvant therapy efforts, current data supporting the use of checkpoint blockade, and a future outlook for adjuvant therapy in renal cell carcinoma.

Idioma originalInglés
Número de artículo926661
PublicaciónFrontiers in Oncology
EstadoPublicada - 29 sep. 2022
Publicado de forma externa

Nota bibliográfica

Publisher Copyright:
Copyright © 2022 Renner, Rojas, Walton-Diaz and Burotto.


Profundice en los temas de investigación de 'Adjuvant therapy for renal cell carcinoma, finally a new standard?'. En conjunto forman una huella única.

Citar esto